NEW YORK, NY / ACCESSWIRE / June 21, 2017 / The Biotech Industry has continued to outperform the broader markets in 2017. Biotech companies appear to be benefitting from a speedier FDA approval process in 2017. There have already been 21 new Novel Drug Approvals so far in 2017, compared to just 22 new approvals in all of 2016.The iShares NASDAQ Biotechnology Index ETF and the SPDR S&P Biotech ETF have posted year-to-date gains of 14.4 and 26.68 percent, respectively, compared to gains of 8.63 percent and 8.85 percent for the Dow Jones Industrial Average and the S&P 500 Index.

RDI Initiates Coverage on:

Gilead Sciences, Inc.
https://ub.rdinvesting.com/news/?ticker=GILD

Sarepta Therapeutics Inc.
https://ub.rdinvesting.com/news/?ticker=SRPT

Gilead Sciences Inc.'s stock moved 1.19% higher Tuesday, to close the day at $65.59. The stock recorded a trading volume of 13.11 million shares, higher than the average daily volume of 7.44 million shares. In the last year Gilead Sciences Inc.'s shares have traded in a range of $63.76 - $88.85. The stock is currently trading 26.18% below its 52 week high. The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $65.54 is below its 200-day moving average of $69.05. Shares of the company are trading at a Price to Earnings ratio of 6.93. Shares of Gilead Sciences have fallen approximately 8.41 percent year-to-date.

On June 12th, the company announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational, once-daily single tablet regimen containing bictegravir (50 mg) (BIC), a novel investigational integrase strand transfer inhibitor, and emtricitabine/tenofovir alafenamide (200/25 mg) (FTC/TAF) for the treatment of HIV-1 infection in adults.

Access RDI's Gilead Sciences Research Report at:
https://ub.rdinvesting.com/news/?ticker=GILD

On Tuesday, shares of Sarepta Therapeutics recorded a trading volume of 1.44 million shares, lower than the average daily volume of 1.60 million shares. The stock ended the day 0.60% higher at $33.51. The share price has gained 102.84% from its 52 week low with a 52 week trading range of $16.52 - $63.73.The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $32.75 is greater than its 200-day moving average of $31.47. Sarepta reported a GAAP net income of $84.1 million, or $1.50 per diluted share, on net revenues of $16.3 million in the first quarter of 2017. The company had $391.1 million in cash, cash equivalents and investments as of March 31, 2017 compared to $329.3 million as of December 31, 2016, an increase of $61.8 million. Shares of Sarepta Therapeutics have gained approximately 22.17 percent year-to-date.

Access RDI's Sarepta Therapeutics Research Report at:
https://ub.rdinvesting.com/news/?ticker=SRPT

Our Actionable Research on Gilead Sciences, Inc. (NASDAQ: GILD) and Sarepta Therapeutics Inc. (NASDAQ: SRPT) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com